The Accessible Canada Directorate within Employment and Social Development Canada (ESDC) has engaged Quorus Consulting Group to conduct the second cycle of public opinion research measuring Canadians’ awareness and experience(s) […]

Menopause is associated with a range of symptoms which may affect quality of life as well may increase an individual’s risk of chronic conditions such as osteoporosis or cardiovascular disease.  […]

As soon as the early signs of spring appear, golfers start counting down the days until their first tee-off of the season! Golfing is a great outdoor sport, a good […]

The National Osteoporosis Foundation and the American Society for Preventive Cardiology formed an expert panel and completed a detailed review of all published research evaluating the effects of calcium intake […]

Osteoporosis Canada advises individuals on denosumab therapy to discuss their treatment with their physician prior to delaying therapy, stopping therapy or missing a scheduled dose.   Denosumab (Prolia) has been […]

Romosozumab EVENITY™ (romosozumab injection) Romosozumab, a sclerostin inhibitor, is the first new approach to the treatment of osteoporosis and fracture risk in almost a decade.Romosozumab (EVENITY™) significantly and rapidly (over […]

Strontium ranelate (Protelos) is a drug approved for the treatment of osteoporosis in Europe, but not in Canada. It is effective in reducing fractures . Recently the European Medicines Agency […]

The release of the Osteoporosis Canada 2023 Clinical Practice Guideline will support Canadian healthcare providers in providing the most current evidence-based information for patient centred care to optimise skeletal health […]